Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.
Summary
This pooled analysis of two phase II clinical trials, MEDITREME and METIMMOX, investigated the efficacy of first-line chemoimmunotherapy in patients with microsatellite stable (MSS) metastatic colorectal cancer. The findings revealed a significant improvement in median overall survival for the chemoimmunotherapy group compared to chemotherapy alone. Additionally, higher complete response rates were observed with the combination therapy. The study also suggests that baseline CD8+ T-cell infiltration could serve as a predictive biomarker to identify patients most likely to benefit from this treatment approach.
Analysis
This pooled analysis of two phase II trials provides compelling clinical evidence supporting first-line chemoimmunotherapy for a subset of patients with MSS metastatic colorectal cancer. The significant improvement in overall survival (HR = 0.58) is a key finding, though being a pooled analysis of phase II data, it warrants confirmation in phase III studies. The identification of CD8+ T-cell infiltration as a predictive biomarker is crucial for patient selection, enabling precision medicine. These results could justify phase III trials and potentially shift clinical practice within 3-5 years for MSS patients with high CD8+ infiltration.